BeiGene Signs an Exclusive Worldwide Collaboration with Shoreline to Develop and Commercialize Genetically Modified NK Cell Therapies

 BeiGene Signs an Exclusive Worldwide Collaboration with Shoreline to Develop and Commercialize Genetically Modified NK Cell Therapies

BeiGene Signs an Exclusive Worldwide Collaboration with Shoreline to Develop and Commercialize Genetically Modified NK Cell Therapies

Shots:

  • Shoreline to receive $45M up front in cash and is eligible to receive R&D funding, milestones along with royalties, following the achievement of certain milestones
  • The companies will jointly develop cell therapies for four targets, with an option to further expand the collaboration. BeiGene will lead the clinical development globally while Shoreline will be responsible for clinical manufacturing
  • BeiGene to get WW commercial rights with Shoreline having an option to retain US and Canadian commercialize rights for two targets out of four. Additionally, BeiGene gets an option to acquire an equity stake in Shoreline in its next round of equity financing for specified conditions

Click here to­ read full press release/ article | Ref: Business Wire | Image: PR Newswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post